BACKGROUND: Serum leptin is associated with the occurrence of cardiovascular risk factors but it is unknown whether leptin is also associated with cardiovascular disease. Another open question is whether the Trp64Arg polymorphism of the b b 3 -adrenergic receptor (b 3 -AR) is a determinant of circulating leptin. OBJECTIVES: We measured serum leptin concentrations in a large group of patients with angiographically assessed coronary artery disease (CAD) and investigated the relationship between the Trp64Arg polymorphism of the b 3 -adrenergic receptor (AR) and serum leptin. PATIENTS AND METHODS: Leptin was measured in the fasting state in 1000 consecutive patients with angiographically con®rmed CAD by radioimmunoassay. The codon 64 TaC polymorphism of the b b 3 -AR gene was analysed by the polymerase chain reactionarestriction fragment length polymorphism (PCRaRFLP) technique. Controls were 1000 age-, gender-and weight-matched subjects without clinical signs of CAD. RESULTS: Serum leptin concentrations were signi®cantly higher in patients with CAD than in those without CAD (median: 6.8 vs 6.1 ngaml, P`0.001). In a multiple regression analysis leptin was found to be a determinant of CAD (P 0.005) along with established risk factors. No differences in serum leptin were observed between wild-type and heterozygous carriers of the Trp64Arg mutation of the b 3 -AR gene, whereas the small group of homozygous carriers had higher leptin due to their higher BMI. In a multiple linear regression analysis, body mass index, gender and fasting insulin were the main signi®cant determinants of serum leptin, whereas the b 3 -AR polymorphism had no effect. CONCLUSIONS: Patients with coronary artery disease exhibit higher serum leptin concentrations than age-and gender-matched controls of comparable BMI, indicating that leptin could contribute to the development of cardiovascular disease, possibly via activation of the sympathetic nervous system. The Trp64Arg variant of the b 3 -adrenoceptor did not in¯uence serum leptin.
Introduction
Leptin is a 16 kDa peptide which is almost exclusively produced by adipocytes and plays an important role in the regulation of energy balance.
1,2 Serum leptin concentrations re¯ect adipose tissue mass, 3 but may also be in¯uenced by pathophysiological conditions such as insulin resistance. 4 It is now well known that leptin is subject to short-term regulation by a variety of hormones and metabolites. 2 Recent data indicate positive associations between serum leptin and metabolic risk factors for cardiovascular disease, 5 but no information is currently available on serum leptin concentrations in patients with coronary artery disease (CAD).
Increasing evidence suggests that leptin has broader actions than originally believed, also including effects on sympathetic nerve and cardiovascular functions. 6 In rodents, systemic administration of leptin increased sympathetic nerve activity in some organs, but did not acutely elevate arterial blood pressure and heart rate, 7 whereas intracerebroventricular infusion of leptin increased both sympathetic nerve activity and blood pressure. 8 In fasted mice, intraperitoneal infusion of leptin was followed by increases of circulating glucose, insulin and glucagon via sympathetic nerves. 9 These ®ndings may be of interest for humans as it is known from clinical trials that a high sympathetic nerve activity is associated with an increased risk of cardiovascular disease. a suppressive effect on leptin production. 11 ± 16 The b 3 -adrenoceptor (b 3 -AR) appears to be critically involved in this down-regulation, at least in rodent adipose tissue. It has been reported that functional b 3 -adrenergic receptors are present in human adipose tissue, particularly in the intra-abdominal fat depots. 17 ± 19 One of these studies postulated that the b 3 -AR plays a pathogenic role for the development of metabolic disturbances in abdominal obesity. 19 Recent studies demonstrated that a mutation of the human b 3 -AR gene, characterized by substitution of arginine for tryptophan at position 64 (Trp64Arg), is associated with increased capacity for body weight gain, features of insulin resistance, and early onset of type-2 diabetes mellitus, 20 ± 22 all considered to be cardiovascular risk factors. However, subsequent studies reported con¯icting results on the functional role of the b 3 -AR polymorphism with respect to body weight gain and metabolic disorders. 23 ± 30 Irrespective of this controversy, it is tempting to speculate that the Trp64Arg polymorphism may be associated with a dysregulation of leptin production and may contribute to elevated serum leptin.
It was consequently the objective of this crosssectional study ®rst to investigate the role of serum leptin as a possible determinant of CAD in humans and, in this context, to examine the contribution of the b 3 -AR polymorphism to serum leptin concentrations in patients with and without CAD.
Patients and methods
Between October 1995 and January 1997, 1000 consecutive Caucasian patients from the Berlin area, who had been admitted for angiography for suspected CAD andaor for elective or emergency interventions, were recruited at the Charite Â University Medical Center. In a case ± control design, an additional 1000 patients matched for age, gender and race served as controls. The patients of the control group had no evidence of CAD or of other cardiovascular diseases on the basis of data from patient histories, physical examination, ECG and echocardiography. We excluded individuals with severe systemic diseases which could have potentially in¯uenced variables of the cardiovascular risk factor pro®le. All cases and controls gave written consent according to the study protocol which was approved by the Ethical Committee of the Charite Â Hospital.
Cases were classi®ed by angiographic criteria. Angiograms were reviewed by experienced cardiologists who were blind to patient identity and outcome. CAD was de®ned as stenosis 50% in at least one major coronary artery or major branch. The severity of CAD was classi®ed according to the number of affected arteries, ie as one-, two-or three-vessel disease. Diagnosis of myocardial infarction was based on both reference of patient case notes using WHO criteria, 31 and angiographical ®ndings; patients with equivocal results were excluded.
Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared (kgam 2 ). Waist-tohip (WHR) was calculated as waist circumference divided by hip circumference (cmacm). Subjects were de®ned as smokers if they were current smokers or had smoked within the last 10 y. All others were classi®ed as non-smokers. Patients were de®ned as having hypertension if they presented with a mean blood pressure 140a90 mmHg on repeated measurements under standardized conditions andaor were under antihypertensive drug treatment.
Laboratory determinations
Blood was collected in the morning after an overnight fast of at least 10 h. EDTA-containing tubes served for analysis of plasma lipids. Total cholesterol, HDLcholesterol and triglycerides were measured by enzymatic methods (Boehringer, Mannheim, Germany). LDL-cholesterol was calculated using the Friedewald formula; apo-A1 and apo-B were determined by immunoturbidimetric assays (Tina-quant, Boehringer Mannheim). Measurement of serum leptin (Linco, St Charles, MO) and insulin (Pharmacia, Freiburg, Germany) were performed by radioimmunoassay according to the instructions of the manufacturers.
A 10 ml venous blood sample, drawn with EDTA as anticoagulant, was obtained from each subject and stored at 720 C. After thawing, erythrocytes were disrupted for 30 min in a hypoosmolaric buffer containing 155 mmolal NH 4 Cl, 10 mmolal KH 2 CO 3 and 0.1 mmolal EDTA, at pH 8.0. Leukocytes were isolated by centrifugation at 1000 g at 4 C for 30 min, resuspended in 20 mmolal Tris ± HCl, 2 mmolal EDTA and 30 mmolal NaCl, at pH 7.5, and stored at 720 C. DNA was isolated manually by a standard three-step phenolachloroform extraction 32 after digestion with proteinase K (Boehringer, Mannheim), or with a 341A Applied Biosystems DNA extractor (Biosystems, Weiterstadt, Germany). DNA was dissolved overnight at 55 C in 10 mmolal Tris and 1 mmolal EDTA buffer (pH 8.0), and stored at 4 C until further analysis.
The TaC point mutation leading to a TrpaArg exchange in codon 64 of the b 3 -AR gene was evaluated by polymerase chain reactionarestriction fragment length polymorphism (PCRaRFLP). Primers were designed from the sequence published by Van Spronsen et al. 33 A 192-bp fragment taken from exon 1 of the b 3 -AR gene was ampli®ed using 0.5 units of AmpliTaq Gold
CAC CGA GGT CCA CAG and 1.0 mmolal MgCl 2 in a ®nal volume of 25 ml. PCR conditions were 45 cycles for 30 s at 94 C, 30 s at 57 C, and 30 s at 72 C using a Perkin-Elmer GeneAmp 1 9600 or 9700 thermocycler. PCR ef®ciency was checked on a 2% agarose gel, for 20 min at 120 V. A 15 ml aliquot of the ampli®ed product was incubated with 90 units of MspI (New England Biolabs, Schwalbach, Germany), in a ®nal volume of 25 ml, at 37 C overnight. Fragments were separated on 3.5% NuSieve 3:1 gel (Biozym, Hessisch Oldendorf, Germany) for 75 min at 100 V. The wild-type presented a constitutive restriction site resulting in a 118-and a 74-bp fragment, whereas mutated alleles presented three fragments of 88, 74, and 30 bp.
Statistical analysis
In this case ± control study each group originally comprised 1000 subjects. Samples were matched for age, gender and race but did not include matched pairs. Values are presented as median and 25th and 75th percentiles. Comparisons with respect to continuous variables were performed using the Mann ± Whitney U-test, as most continuous variables were not normally distributed, even after log transformation. Differences in frequencies were tested by w 2 -test. We employed multiple logistic regression analysis with CAD as dependent variable including age, BMI, gender, leptin, fasting insulin, diabetes, smoking, hypertension and hypercholesterolaemia, to examine the relationship between leptin and CAD. Determinants of serum leptin levels were further analysed by linear regression analysis with BMI, gender, b 3 -AR genotypes and other possible determinants as covariates. Table 1 presents selected characteristics of the case and the control group including risk factors for CAD. The groups were comparable for age, gender distribution, BMI and waistahip ratio, but differed signi®-cantly with respect to the prevalence of diabetes mellitus, hypercholesterolaemia, hypertension, and smoking Ð as well as for serum concentrations of triglycerides, total cholesterol, LDL-cholesterol, apo-A1 and apo-B. The case group demonstrated varying degrees of severity of CAD; 66.7% suffered from acute myocardial infarction or had a history of previous myocardial infarction.
Results
Serum leptin was found to be signi®cantly higher in the subjects with angiographically assessed CAD compared to the control subjects (6.8 vs 6.1 ngaml, P`0.001; Mann ± Whitney U-test; Table 1 ). This was also true when males and females were analysed separately (males: 5.8 vs 5.0 ngaml; females, 15.9 vs 12.8 ngaml, each P`0.01; Mann ± Whitney U-test). In addition, fasting insulin was elevated in the patients with CAD as compared to controls without evidence of CAD (13.3 vs 11.5 mUaml, P`0.001; Mann ± Whitney U-test). Presence of diabetes, hypertension and hypercholesterolaemia were associated with higher plasma leptin concentrations, whereas smokers had lower leptin concentrations than non-smokers, both in the cases and controls (Table 2 ). In a multiple logistic regression analysis with CAD as dependent variable, serum leptin was found to be an independent determinant of angiographically assessed coronary heart disease in addition to other established cardiovascular risk factors (Table 3) .
When both groups were subdivided according to the b 3 -AR genotype, the respective difference in leptin Differences between groups were tested using the Mann ± Whitney U-test for continuous variables and w 2 -test (*), respectively.
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concentrations between the patients with CAD and the control subjects remained unchanged, but was statistically signi®cant only in the wild-type group and the group of homozygote carriers of the mutation (Table  4) . A striking ®nding in the case group was that leptin concentrations were almost twice as high among the nine homozygous carriers than among both the wildtype and heterozygous carriers (14.1 vs 6.8 and 6.7 ngaml, respectively; P`0.01 each). In the control group, serum leptin also tended to be higher in the homozygous carriers than in the two other subgroups (Table 4) . In Figure 1 , leptin was plotted against BMI for the wild-type and the heterozygote variant strati®ed for gender and group. Only in the females with the TrpaArg genotype did the regression lines differ between cases and controls, indicating that female heterozygote carriers of the Trp64Arg mutation in the CAD group had higher leptin concentrations at a given BMI than the female heterozygote carriers of the control group. The carriers with the ArgaArg genotype were excluded from this analysis due to the small number of subjects. We ®nally investigated which factors contributed to serum leptin concentrations. A multiple linear regression analysis was performed for cases and controls separately. This calculation revealed that in the case group gender, BMI, fasting insulin, age and presence of diabetes were signi®cant determinants of serum leptin, whereas in the control group gender, BMI and fasting insulin independently contributed to serum leptin (Table 5 ). In contrast, the other variables in the model including the b 3 -AR genotype had no signi®cant effect on serum leptin concentrations.
Discussion
The recent identi®cation and characterization of leptin introduced a new candidate which may contribute to some of the metabolic disturbances associated with obesity 2,4 and, subsequently, also with its consequences, particularly cardiovascular disease. In clinical studies, plasma concentrations of leptin were found to be positively associated with insulin resistance and metabolic risk factors for cardiovascular disease. 5 However, to date no information is available on the relationship between circulating leptin levels and coronary artery disease.
On the basis of a large sample of patients, we now report higher serum leptin concentrations in subjects with angiographically assessed CAD as compared to controls without clinical evidence of CAD, although both groups were comparable with regard to age and gender distribution and did not differ in BMI. The statistical analysis using a multiple regression model showed that serum leptin was a signi®cant determinant of CAD in addition to other established cardiovascular risk factors. However, it must be kept in mind that the design of the study does not allow the conclusion that leptin is a causal risk factor for coronary artery disease. To study a possible cause ± effect relationship a prospective study would be necessary.
How can the association between leptin and CAD be explained? It is well known that leptin increases the activity of the sympathetic nervous system. 2, 6 This has been demonstrated in animal studies after administration of leptin into the cerebroventricular¯uid or at peripheral sites. 7 ± 9 In a recent study in healthy adult subjects by Snitker et al, there was a positive correlation between basal muscle sympathetic nerve activity Hypertension present 7.7 (4.9 ± 13.6) 7.5 (4.4 ± 13.6) Hypertension absent 6.0 (3.8 ± 9.6) 5.4 (3.1 ± 9.5) P-value`0.001`0.001 Hypercholesterolaemia present 7.0 (4.6 ± 11.8) 7.2 (4.1 ± 12.2)
Hypercholesterolaemia absent 6.6 (4.0 ± 10.9) 5.8 (3.3 ± 9.9) P-value 0.037`0.001 Smokers 6.4 (3.9 ± 10.5) 5.2 (2.7 ± 9.0) Non-smokers 7.1 (4.5 ± 11.9) 6.8 (4.1 ± 11.8) P-value 0.008`0.001 a Mann ± Whitney U-test. 34 However, the situation is complicated by the fact that body fat is associated with both leptin and MSNA, by the poorly characterized phenomenon of leptin resistance, 3 by the possible stimulatory effect of insulin on MSNA 36 and by the observation that an increased sympathetic out¯ow in turn may decrease leptin production in adipose tissue. 11 ± 16 Therefore, further detailed studies are required to obtain a better understanding of the role of leptin in the regulation of the sympathetic nervous system in humans.
In a further analysis gender, BMI and fasting insulin proved to be signi®cant determinants of serum leptin. Separate effects were also observed for age and the presence of diabetes in the patients with CAD. In contrast, the b 3 -AR genotype and the other parameters used in the model including hypercholesterolaemia, hypertension and smoking had no signi®-cant in¯uence on serum leptin. As gender distribution and BMI were similar between the two groups, although the latter gives only limited information on percentage body fat, the role of fasting insulin is an interesting ®nding. The moderately elevated leptin concentrations in patients with CAD, but also in patients with cardiovascular risk factors such as hypertension, could be at least partially due to the higher insulin levels compared with the control group. It is well established that insulin is able to increase leptin production in cultured human fat cells. 37 Furthermore, clinical studies using the euglycaemic ± hyperinsulinaemic clamp technique indicate that prolonged hyperinsulinaemia increases serum leptin levels in a dose-dependent fashion. 38 There is some evidence that the b 3 -AR may be involved in the pathogenesis of at least some obesitylinked metabolic disturbances. 19 This adrenergic receptor subtype was recently found to be expressed in human adipose tissue, particularly in the omental fat depot, 17 and may contribute to the regulation of catecholamine-induced lipolysis. 18 To date, there is no information available on the role of the b 3 -AR in leptin production in humans, whereas in animals b 3 -AR agonists were found to be potent suppressors of leptin production. 11 ± 14 Clinical studies reported an association between a polymorphism of the b 3 -adrenoceptor at codon 64 and 23 ± 30 Irrespective of this controversy, we tested the hypothesis that a possible dysfunction of the b 3 -AR due to a mutation at codon 64 could affect leptin production in adipose tissue and may result in elevations of serum leptin concentrations. However, the results presented here clearly indicate that at least the heterozygous form of the mutation has no physiologically signi®cant effect on serum leptin. An interesting ®nding was that serum leptin concentrations were elevated among the homozygous carriers of the b 3 -AR polymorphism. It appears justi®ed to assume that this observation is the result of the enlarged body-fat mass in this group rather than of diminished suppression of leptin production due to the mutation. The mean BMI in the small group of homozygote carriers of the mutation was signi®cantly higher than in the carriers of the wild-type and the heterozygous mutation (median BMI: 28.0 vs 26.1 vs 26.0 kgam 2 ).
In conclusion, the results of this study reveal: (1) higher serum concentrations of leptin in patients with angiographically assessed CAD as compared to ageand gender-matched controls with similar BMI which may support the hypothesis that leptin is a determinant of cardiovascular disease possibly via its stimulatory action on the sympathetic nervous system; and (2) the lack of an association between the Trp64Arg polymorphism of the b 3 -AR gene and serum leptin arguing against a dysregulation of leptin production by this mutation. The elevated leptin concentrations in patients with coronary artery disease may partially be the consequence of elevated serum insulin concentrations which are also known to activate sympathetic nerve activity. Further prospective studies are required to assess the role of leptin in the pathogenesis of coronary artery disease.
